Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Gastroenterology

Volumn 128, Issue 2, 2005, Pages 270-279

  Debiec Rychter, Maria ^a   Cools, Jan ^b   Dumez, Herlinde ^a   Sciot, Raf ^a   Stul, Michel ^a   Mentens, Nicole ^b   Vranckx, Hilde ^a   Wasag, Bartosz ^a,c   Prenen, Hans ^a   Roesel, Johannes ^d   Hagemeijer, Anne ^a   Van Oosterom, Allan ^a   Marynen, Peter ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MIDOSTAURIN; MUTANT PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE; STAUROSPORINE; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GASTROINTESTINAL TUMOR; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING; DRUG ANTAGONISM; DRUG RESISTANCE; EXON; GASTROINTESTINAL STROMAL TUMOR; GENETICS; MIDDLE AGED; MUTATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STAUROSPORINE;

EID: 14944352767     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.11.020     Document Type: Article

References (28)

1. S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, S. Ishiguro, K. Kawano, M. Hanada, A. Kurata, M. Takeda, G. Muhammad Tunio, Y. Matsuzawa Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577 580
2. B.P. Rubin, S. Singer, C. Tsao, A. Duensing, M.L. Lux, R. Ruiz, M.K. Hibbard, C.-J. Chen, S. Xiao, D.A. Tuveson, G.D. Demetri, C.D.M. Fletcher KIT activation is a ubiquitous feature of gastrointestinal stromal tumors Cancer Res 61 2001 8118 8121
3. M.C. Heinrich, C.L. Corless, A. Duensing, L. McGreevey, C.-J. Chen, N. Joseph, S. Singer, D.J. Griffith, A. Haley, A. Town, G.D. Demetri, C.D.M. Fletcher, J.A. Fletcher PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 2003 708 710
4. A.T. Van Oosterom, I.R. Judson, J. Verweij, S. Stroobants, E. Donato di Paola, S. Dimitrijevic, M. Martens, A. Webb, R. Sciot, M. Van Glabbeke, S. Silberman, O.S. Nielsen Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal tumors a phase I study Lancet 358 2001 1421 1423
5. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, P.J. Roberts, M.C. Heinrich, D.A. Tuveson, S. Singer, M. Janicek, J.A. Fletcher, S.G. Silverman, S.L. Silberman, R. Capdeville, B. Kiese, B. Peng, S. Dimitrijevic, B.J. Druker, C. Corless, C.D.M. Fletcher, H. Joensuu Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
6. B.J. Longley, M.J. Reguera, Y. Ma Classes of c-KIT activating mutations proposed mechanisms of action and implications for disease classification and therapy Leuk Res 25 2001 571 576
7. D.A. Tuveson, N.A. Willis, T. Jacks, J.D. Griffin, S. Singer, C.D. Fletcher, G.D. Demetri STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications Oncogene 20 2001 5054 5058
8. M.C. Heinrich, C.L. Corless, G.D. Demetri, C.D. Blanke, M. von Mehren, H. Joensuu, L.S. McGreevey, C.-J. Chen, A.D. Van den Abbeele, B.J. Druker, B. Kiese, B. Eisenberg, P.J. Roberts, S. Singer, C.D.M. Fletcher, S. Silberman, S. Dimitrijevic, J.A. Fletcher Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 2003 4342 4349
9. M. Debiec-Rychter, H. Dumez, I. Judson, B. Wasag, J. Verweij, M. Brown, S. Dimitrijevic, R. Sciot, M. Stul, H. Vranckx, M. Scurr, A. Hagemeijer, M. Van Glabbeke, A.T. van Oosterom Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 40 2004 689 695
10. Y. Ma, S. Zeng, D.D. Metcalfe, C. Akin, S. Dimitrijevic, J.H. Butterfield, G. McMahon, B.J. Longley The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations Blood 99 2002 1741 1744
11. M.J. Frost, P.T. Ferrao, T.P. Hughes, L.K. Ashman Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-KIT whereas the kinase domain mutant D816VKit is resistant Mol Cancer Ther 1 2002 1115 1124
12. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, C.L. Sawyers Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
13. J. Cools, D.J. DeAngelo, J. Gotlib, E.H. Stovar, M. Phil, R.D. Legare, J. Cortes, J. Kutok, J. Clark, I. Galinsky, J.D. Griffin, N.C.P. Cross, A. Tefferi, J. Malone, R. Alam, S.L. Schrier, J. Schmid, M. Rose, P. Vandenberghe, G. Verhoef, M. Boogaerts, I. Wlodarska, H. Kantarijan, P. Marynen, S.E. Coutre, R. Stone, D.G. Gilliland A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic heteroeosinophilic syndrome N Engl J Med 348 2003 1201 1214
14. J. Cools, E.H. Stover, C.L. Boulton, J. Gotilb, R.D. Legare, S.M. Amaral, D.P. Curley, N. Duclos, R. Rowan, J.L. Kutok, B.H. Lee, I.R. Williams, S.E. Coutre, R.M. Stone, D.J. DeAngelo, P. Marynen, P.W. Manley, T. Meyer, D. Fabbro, D. Neuberg, E. Weisberg, J.D. Griffin, D.G. Gilliland PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRA-induced myeloproliferative disease Cancer Cell 3 2003 459 469
15. J.A. Fletcher, C.L. Corless, S. Dimitrijevic, B. Von Mehren, H. Eisenberg, H. Joensuu, C.D.M. Fletcher, C. Blanke, G.D. Demetri, M.C. Heinrich Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumors (GIST) (abstr 3275) Proc ASCO 22 2003 815
16. E. Tamborini, L. Bonadiman, A. Greco, V. Albertini, T. Negri, A. Gronchi, R. Bertulli, M. Colecchia, P.G. Casali, M.A. Pierotti, S. Pilotti A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 2004 294 299
17. T. Wakai, T. Kanda, S. Hirota, A. Ohashi, Y. Shirai, K. Hatakeyama Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumor is associated with a second KIT mutation Br J Cancer 90 2004 2059 2061
18. E. Andrejausksas-Buchdunger, U. Regenass Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251 Cancer Res 52 1992 5353 5358
19. D. Fabbro, S. Ruetz, E. Buchdunger, S.W. Cowan-Jacob, G. Fendrich, J. Liebetanz, J. Mestan, T. O'Reilly, P. Traxler, B. Chaudhuri Protein kinases as targets for anticancer agents from inhibitors to useful drugs Pharmacol Ther 93 2002 79 98
20. E. Weisberg, C. Boulton, L.M. Kelly, P. Manley, D. Fabbro, T. Meyer, D.G. Gilliland, J.D. Griffin Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412 Cancer Cell 1 2002 433 443
21. M. Debiec-Rychter, B. Wasag, M. Stul, I. De Wever, A. Van Oosterom, R. Sciot GISTs negative for KIT(CD117) immunoreactivity J Pathol 202 2004 430 438
22. S. Hirota, T. Nishida, K. Isozaki, M. Taniguchi, K. Nishikawa, A. Ohashi, A. Takabayashi, T. Obayashi, T. Okuno, K. Kinoshita, H. Chen, Y. Shinomura, Y. Kitamura Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene Gastroenterology 122 2002 1493 1499
23. H. Chen, K. Isozaki, K. Kinoshita, A. Ohashi, Y. Shinomura, Y. Matsuzawa, Y. Kitamura, S. Hirota Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors Int J Cancer 105 2003 130 135
24. J.J. Clark, J. Cools, D.P. Curley, J.C. Yu, N.A. Lokher, N.A. Giese, D.G. Gilliland Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518 Blood 104 2004 2867 2872
25. K. Kemmer, C.L. Corless, J.A. Fletcher, L. McGreevey, A. Haley, D. Griffith, O.W. Cummings, C. Wait, A. Town, M.C. Heinrich KIT mutations are common in testicular seminomas Am J Pathol 164 2004 305 313
26. D.J. Propper, A.C. McDonald, A. Man, P. Thavasu, F. Balkwill, J.P. Braybrooke, F. Caponigro, P. Graf, C. Dutreix, R. Blackie, S.B. Kaye, T.S. Ganesan, D.C. Talbot, A.L. Harris, C. Twelves Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C J Clin Oncol 19 2001 1485 1492
27. J. Gotlib, C. Berube, J. Ruan, J. Growney, K. Dugan, R. Falkow, M. Rosamilia, D. Resta, P. Cohen, D. Fabbro, M. Heinrich, D.G. Gilliland, S. Coutre PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficiacy in mast cell leukemia with the D816V KIT mutation Blood 102 2003 919A
28. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2004 Sep 2 [Epub ahead of print].